Abeona Therapeutics Inc. (LON:0H7R)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 233.22M +10.2% |
| Revenue (ttm) | 19.23M +6,280.0% |
| Net Income | -47.40M |
| EPS | -0.89 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,650 |
| Open | 5.50 |
| Previous Close | 5.46 |
| Day's Range | 5.38 - 5.50 |
| 52-Week Range | 3.84 - 8.25 |
| Beta | 1.32 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Abeona Therapeutics
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platfor... [Read more]
News
Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111
Abeona Therapeutics (ABEO) “congratulated” Ultragenyx Pharmaceutical (RARE) on the U.S. Food and Drug Administration, FDA, approval of FAYUVI, also known as UX111, a gene therapy for the treatment of ...
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona's foundational R&D and clinical development efforts -
Abeona Therapeutics price target raised to $30 from $28 at Cantor Fitzgerald
Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Abeona Therapeutics (ABEO) to $30 from $28 and keeps an Overweight rating on the shares. Abeona’s partner Ultragenyx (RARE)…
Abeona Therapeutics initiated with a Buy at Roth Capital
Roth Capital initiated coverage of Abeona Therapeutics (ABEO) with a Buy rating and $17 price target The firm cites Zevaskyn’s “durable” profile targeting recessive dystrophic epidermolysis bullosa fo...
Abeona Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted the commercial launch of a novel gene therapy for a severe genetic skin disorder, emphasizing its unique durability, operational challenges, and expanding treatment center network. Key metrics for future growth include patient treatment cadence, site activation, and manufacturing scalability.
Abeona activates UF Health as qualified treatment center for Zevaskyn
Abeona Therapeutics (ABEO) announced the activation of University of Florida Health in Gainesville, Florida, as the eighth qualified treatment center, or QTC, for the administration of Zevaskyn gene-m...
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet ne...
Abeona Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Strong commercial momentum for ZEVASKYN is supported by expanding treatment centers, robust payer coverage, and durable clinical outcomes. Pipeline progress includes key partnerships and a new prostate cancer asset, with multiple inflection points expected in the next year.
Abeona Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
ZEVASKYN's launch is progressing with expanding access, strong payer coverage, and positive early patient outcomes, while manufacturing and site capacity are scaling to meet demand. The pipeline and partnered programs offer additional revenue potential, and foundational work in 2024 is expected to drive significant growth by 2026–2027.
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $ABEO--ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law.
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
CLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September...
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awa...
Abeona Therapeutics reports Q2 EPS (35c), consensus (25c)
Reports Q2 revenue $11.38M, consensus $12.16M. “Our confidence in ZEVASKYN’s substantial opportunity is reinforced by our launch progress and experience to date as we engage with a growing number of…
Abeona Therapeutics price target lowered to $21 from $22 at Oppenheimer
Oppenheimer analyst Jeff Jones lowered the firm’s price target on Abeona Therapeutics (ABEO) to $21 from $22 and keeps an Outperform rating on the shares following quarterly results. The firm…
Abeona Therapeutics price target lowered to $15 from $20 at Alliance Global
Alliance Global lowered the firm’s price target on Abeona Therapeutics (ABEO) to $15 from $20 and keeps a Buy rating on the shares. The firm cites a moderate Zevaskyn adoption…
Abeona Therapeutics Earnings Call Transcript: Q2 2026
ZEVASKYN's Q2 2026 revenue rose 31% to $11.4M, with seven QTCs now active and 12 patients treated since launch. Operational and manufacturing challenges affected revenue recognition for some treatments, but CMS NTAP status and expanding access support future growth.
Abeona Therapeutics Quarterly report: Q2 2026
Abeona Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Abeona Therapeutics Earnings release: Q2 2026
Abeona Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
- Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since launch, 12 treatments c...
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
CLEVELAND, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company will host a conference call on Thursday, August 13, 2026 at 8:30 a.m. ET to discus...
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
CLEVELAND, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announ...
Abeona Therapeutics activates Cincinnati Children’s as treatment center
Abeona Therapeutics (ABEO) announced the activation of Cincinnati Children’s as the seventh Qualified Treatment Center for the administration of Zevaskyn. Zevaskyn is an autologous gene-modified cellu...
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
CLEVELAND, July 21, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announ...
Abeona Therapeutics Transcript: AGM 2026
The meeting addressed director elections, executive compensation, auditor ratification, and equity plan amendments. All proposals passed except the amendment to remove the advance notice provision for director nominations.
Abeona Therapeutics Slides: Investor presentation
Abeona Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 10, 2026.